

**AGIMEXPHARM PHARMACEUTICAL  
JOINT STOCK COMPANY**

No.: 05/CV-AGP

*Re: Clarification on the over 10% fluctuation in profit  
after tax in the 2025 reviewed semi-annual financial  
statements compared to the same period*

**THE SOCIALIST REPUBLIC OF VIETNAM  
Independence - Freedom - Happiness**

*An Giang, August 11, 2025*

**To: - STATE SECURITIES COMMISSION  
- HANOI STOCK EXCHANGE**

**1. Organization Name: AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

- Exchange: UPCOM - Securities symbol: AGP

- Address: 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province.

- Contact phone: 02963.856 960 Fax: 02963.957.434

Type of disclosed information: ☒ 24 hours ☐ 72 hours ☐ as required ☐ extraordinary ☐ periodic

**2. Disclosure information content:** Explanation for the over 10% increase in profit after tax in the Statement of Profit or Loss of the 2025 semi-annual financial statements compared to the same period.

Items	Code	Six months ended 30 June 2025	Six months ended 30 June 2024	Change	Ratio
Net sales	10	407.925.440.306	371.008.778.403	36.916.661.903	9,95%
Cost of sales	11	291.752.118.991	265.982.938.952	25.769.180.039	9,69%
Gross profit	20	116.173.321.315	105.025.839.451	11.147.481.864	10,61%
Financial income	21	274.353.608	258.754.611	15.598.997	6,03%
Financial expenses	22	20.856.576.319	15.836.773.867	5.019.802.452	31,70%
Selling expenses	25	46.914.133.258	42.619.903.826	4.294.229.432	10,08%
General and administration expenses	26	21.478.189.285	19.432.079.820	2.046.109.465	10,53%
Net operating profit	30	27.198.776.061	27.395.836.549	-197.060.488	-0,72%
Other profit	40	3.158.571.633	-194.639.266	3.353.210.899	1722,78%
Total accounting profit before tax	50	30.357.347.694	27.201.197.283	3.156.150.411	11,60%
Profit after tax	60	24.450.471.725	21.891.610.223	2.558.861.502	11,69%

Revenue for the first six months of 2025 increased by 9,95% compared to the same period last year, while input costs rose insignificantly, notably financial expenses which increased by 31,7%, affecting the operating results from sales activities. However, during the period, the Company recorded other profit from the disposal of unused assets to optimize the efficiency of existing assets, resulting in profit after tax for the first six months of 2025 increasing by 11,69% compared to the same period.

Sincerely./.

**Recipients:**

- As stated above;
- Archived: VT.

**GENERAL DIRECTOR**  
  
**PHARM. NGUYEN VAN KHA**